Early safety check: testing new drug in people with liver issues
NCT ID NCT07219550
Summary
This early-stage study aims to understand how liver impairment affects how the body processes an experimental drug called MK-1084 (calderasib). Researchers will compare drug levels and safety in 58 participants, some with stable liver disease and some who are healthy. The goal is to gather basic safety and dosing information for future studies, not to treat any disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arizona Clinical Trials ( Site 0003)
RECRUITINGChandler, Arizona, 85225, United States
Contact Phone: •••-•••-••••
-
Orlando Clinical Research Center ( Site 0001)
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
-
The Texas Liver Institute ( Site 0002)
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.